Lipid Nanoparticles
Alkynyl-containing aminolipid compounds enhance gene delivery efficiency by stabilizing in circulation and degrading in endosomes/lysosomes, addressing stability and degradation issues in non-viral vectors, with a synthesis method providing high yield and ease of production.
Patent Information
- Application Number
- JP2023512431
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2020-08-20
- Filing Date
- 2021-08-12
- Publication Date
- 2024-12-09
- Estimated Expiration
- 2041-08-12
AI Technical Summary
Current gene delivery methods face challenges such as the instability of nucleic acids in circulation, degradation by nucleases, and low efficiency in escaping endosomes/lysosomes, limiting the effectiveness of non-viral vectors for gene therapy.
Development of alkynyl-containing aminolipid compounds that remain stable in circulation and rapidly degrade in endosomes/lysosomes, enhancing delivery efficiency, along with a method for easy synthesis under mild conditions.
The alkynyl-containing aminolipid compounds significantly improve mRNA release and delivery efficiency, while the synthesis method offers high yield and ease of operation.
Smart Images

Figure 0007595984000001 
Figure 0007595984000002 
Figure 0007595984000003
Abstract
Description
[Technical field]
[0001] The present invention relates to an amino lipid compound, a method for preparing the same, and lipid particles containing the amino lipid compound. The lipid particles can be used to deliver bioactive agents to cells. The present invention also relates to the use of lipid particles containing amino lipids as pharmaceuticals. [Background technology]
[0002] Gene therapy is the delivery of genes with specific genetic information to target cells by artificial means, and the expressed target protein has the effect of regulating, treating, and even curing diseases caused by congenital or acquired genetic defects. Both nucleic acids and cell membranes are negatively charged. Therefore, naked nucleic acids are difficult to directly introduce into cells, and are easily degraded by nucleases in the cytoplasm, and the effect of gene introduction and gene therapy cannot be achieved. Therefore, it is necessary to use external force or vector to carry out gene delivery.
[0003] Although the advantages of gene therapy are obvious, the lack of safety and high efficiency of gene vectors has prevented gene therapy from being widely used in clinical practice. Gene vectors are generally divided into viral vectors and non-viral vectors. Viral vectors have high transfection efficiency in vivo and in vitro, but also have many defects such as high toxicity, strong immune response, small gene capacity, poor targeting, and complicated preparation methods. Non-viral vectors have attracted more and more attention due to their ease of preparation, transportation, storage, safety, efficacy, and non-immunogenicity.
[0004] However, compared with gene delivery at the cellular level, gene delivery currently faces two problems during treatment. First, free RNA is easily digested by nucleases in plasma. A frequently used solution is to introduce phosphonates loaded with PEG chains into nanoparticles, where the PEG chains extend in the outermost layer of the micelle during self-assembly. The PEG layer has properties such as electroneutrality, resistance to protein adsorption, and no functional groups at the end groups, which can reduce the cytotoxicity of nanovectors in vivo and extend the cycle time. Second, after endocytosis, the gene vector is transported to endosomal / lysosomal vesicles, where the gene is easily degraded by enzymes or acidic substances abundantly contained in lysosomes. Therefore, whether the nucleic acid can escape from the endosome / lysosome and enter the cytoplasm is an important part of gene delivery by non-viral vectors. In the endosomal / lysosomal pathway, the nanocomplex undergoes a process of changing acidity from late endosomes with a pH of 5-6 to lysosomes with a pH of about 4.5. On the other hand, lysosomes are rich in numerous lysosomal enzymes that can easily degrade nanocomplexes. Commonly used non-viral vectors have very low endosomal / lysosomal escape efficiency. Therefore, endosomal / lysosomal escape is a key step to improve gene transfection from non-viral vectors. Disclosed herein are alkynyl-containing amino lipids that simultaneously contain multiple alkyl chains, which show excellent ability to deliver nucleic acids to cells in in vivo delivery studies, significantly superior to the positive control (DLin-MC3) and the corresponding alkynyl-free amino lipids. Summary of the Invention [Problem to be solved by the invention]
[0005] One object of the present invention is to provide amino lipid compounds having an alkyl chain that includes an alkynyl group, that remain stable in the circulation in vivo, that can be rapidly degraded in endosomes / lysosomes, and that have significantly enhanced delivery efficiency.
[0006] Another object of the present invention is to provide a method for preparing novel amino lipid compounds, which has easy availability of raw materials, mild reaction conditions, good reaction selectivity, high yield, low requirements for equipment and apparatus, and simple operation.
[0007] Another object of the present invention is to provide lipid nanoparticles comprising an amino lipid compound. [Means for solving the problem]
[0008] One aspect of the invention is a lipid nanoparticle having formula I:
[0009] [ka]
[0010] (In the formula, G 1 and G 2 are the same or different, and each independently represents -O(C=O)-, -(C=O)O-, -C(=O)-, -O-, -S(O) p -, -SS-, -C(=O)S-, -SC(=O)-, -NR a C(=O)-, -C(=O)NR a -, -NR a C(=O)NR a -, -OC(=O)NR a -OR-NR a C(═O)O—, p=0, 1 or 2; R a is H or C1~C 12 is a hydrocarbyl; L 1 , L 2 , L 3 , L 4 and L 5 are the same or different, and each independently represents C1 to C 24 Alkylene, C2-C 24alkenylene, C3-C8 cycloalkylene, C3-C8 cycloalkenylene, or an optionally substituted 4-10 membered heterocycle containing a heteroatom selected from nitrogen, sulfur and oxygen; 24 Alkylene, C2-C 24 Alkenylene, C3-C8 cycloalkylene and C3-C8 cycloalkenylene are optionally substituted by one or more substituents selected from hydrocarbyl, carboxyl, acyl and alkoxy; R 2 Branch C6~C 24 Alkyl or branched C6-C 24 alkenyl, R 1 and R 3 are the same or different, and each independently represents H, OR 1a , CN, -C(=O)OR 1a , -OC(=O)R 1a , -NR 1b C(=O)R 1a or -NR 1a R 1b Selected from R 1a and R 1b are H or C1 to C 12 (hydrocarbyl) or a pharma- ceutically acceptable salt, prodrug or stereoisomer thereof.
[0011] Another aspect of the present invention is an amino lipid compound having the formula I
[0012] [ka]
[0013] (In the formula, G 1 and G 2 are the same or different, and each independently represents -O(C=O)-, -(C=O)O-, -C(=O)-, -O-, -S(O) p -, -SS-, -C(=O)S-, -SC(=O)-, -NR aC(=O)-, -C(=O)NR a -, -NR a C(=O)NR a -, -OC(=O)NR a -OR-NR a C(═O)O—, p=0, 1 or 2; R a is H or C1~C 12 is a hydrocarbyl; L 1 , L 2 , L 3 , L 4 and L 5 are the same or different, and each independently represents C1 to C 24 Alkylene, C2-C 24 alkenylene, C3-C8 cycloalkylene, C3-C8 cycloalkenylene, or an optionally substituted 4-10 membered heterocycle containing a heteroatom selected from nitrogen, sulfur and oxygen; 24 Alkylene, C2-C 24 Alkenylene, C3-C8 cycloalkylene and C3-C8 cycloalkenylene are optionally substituted by one or more substituents selected from hydrocarbyl, carboxyl, acyl and alkoxy; R 2 Branch C6~C 24 Alkyl or branched C6-C 24 alkenyl, R 1 and R 3 are the same or different, and each independently represents H, OR 1a , CN, -C(=O)OR 1a , -OC(=O)R 1a , -NR 1b C(=O)R 1a or -NR 1a R 1b Selected from R 1a and R 1b are H or C1 to C 12 (hydrocarbyl) or a pharma- ceutically acceptable salt, prodrug or stereoisomer thereof.
[0014] Preferably, the compound has the following structure:
[0015] [ka]
[0016] (In the formula, m and n are the same or different and each independently represents an integer of 1 to 12.) has.
[0017] Preferably, the compound has the following structure:
[0018] [ka]
[0019] (In the formula, x, y, m, and n are the same or different and each independently represents an integer of 1 to 12.) has.
[0020] Preferably, the compound has the following structures (IVa) and (IVb):
[0021] [ka]
[0022] (In the formula, L 1 , L 2 , L 3 , L 4 , and L 5 are the same or different, and each independently represents C1 to C 12 Alkylene, C2-C 12 alkenylene, C3-C8 cycloalkylene, and C3-C8 cycloalkenylene). has one of the following:
[0023] Preferably, the compound has the following structures (Va) and (Vb):
[0024] [ka]
[0025] (In the formula, x, y, m, and n are the same or different and each independently represents an integer of 1 to 12.) has one of the following:
[0026] Preferably, R in the compound 3 is H.
[0027] Preferably, R in the compound 2 has the following structure:
[0028] [ka]
[0029] The compound is selected from those having the following formula:
[0030] More preferably, the compound of formula (I) is G 1 and G 2 are the same or different and each independently selected from -O(C=O)- and -(C=O)O-; L 1 , L 2 , L 3 , L 4 and L 5 are the same or different, and are each independently non-existent, or C1 to C 13 represents alkylene or C4-C6 cycloalkyl, R 1 and R 3 are the same or different, and each independently represents H, OR 1a , CN, 4-6 membered saturated heterocyclyl containing 1 or 2 heteroatoms selected from N and O, -OC(=O)R 1a , -NR 1b C(=O)R 1a or -NR 1a R 1b Selected from R 1a and R 1b are H or C1 to C12 is alkyl, R 2 However, branch C6~C 24 Alkyl It is characterized by:
[0031] More preferably, the compound of formula (I) is G 1 and G 2 are the same or different and each independently selected from -O(C=O)- and -(C=O)O-; L 1 But, C1~C 13 alkylene or C4-C6 cycloalkyl; L 2 , L 3 , L 4 and L 5 are the same or different, and each is independently non-existent or C1 to C 13 represents alkylene, R 1 But, OR 1a , CN, N, and O; 4- to 6-membered saturated heterocyclyl containing 1 or 2 heteroatoms selected from the group consisting of -OC(=O)R 1a , -NR 1b C(=O)R 1a or -NR 1a R 1b Selected from R 1a and R 1b are each H or C1-C6 alkyl, R 2 However, branch C6~C 24 is alkyl, R 3 is C1-C6 alkyl It is characterized by:
[0032] More preferably, the compound of formula (I) is G 1 and G 2 are the same or different and each independently selected from -O(C=O)- and -(C=O)O-; L 1 is C1-C6 alkylene or C4-C6 cycloalkyl, L2 is heptylene, L 3 But C4~C 13 is alkylene, L 4 is absent or represents C1-C3 alkylene; L 5 is C2-C8 alkylene; R 1 is selected from OH, CN, morpholinyl, -OC(=O)(CH2)4CH3, -NHC(=O)(CH2)4CH3, and -N(CH3)2; R 2 but,
[0033] [ka]
[0034] is selected from R 3 is methyl It is characterized by:
[0035] The present invention provides the following representative compounds.
[0036] [Table 1A]
[0037] [Table 1B]
[0038] [Table 1C]
[0039] [Table 1D]
[0040] [Table 1E]
[0041] Another aspect of the present invention is a method for preparing an amino lipid compound comprising the steps of: (1)XL 2 -G 1 -R 2 and a compound represented by R 1 -L 1 -NH2 in the presence of an organic base to form a compound represented by R 1 -L 1 -NH-L 2 -G 1 -R 2 wherein X is a halogen and the organic base is preferably triethylamine, pyridine, DMAP, N,N-diisopropylethylamine, or First, HO-L 2 -G 1 -R 2 in the presence of Dess-Martin periodinane, and then reacting the resulting product with R 1 -L 1 -NH2 in the presence of borohydride to give R 1 -L 1 -NH-L 2 -G 1 -R 2 wherein the borohydride is preferably sodium triacetoxyborohydride, sodium borohydride, potassium borohydride, sodium cyanoborohydride or potassium cyanoborohydride; (2)R 1 -L 1 -NH-L 2 -G 1 -R 2 A compound represented by the formula:
[0042] [ka]
[0043] to produce an amino lipid compound, X being a halogen, preferably the reaction is carried out in the presence of a base and a catalyst, the base being selected from an organic base or an inorganic base, the organic base being selected from triethylamine, pyridine, DMAP, and N,N-diisopropylethylamine, the inorganic base being selected from sodium carbonate, potassium carbonate, sodium bicarbonate, potassium bicarbonate, sodium hydroxide, potassium hydroxide, sodium hydride, or potassium hydride, and the catalyst being selected from iodine particles, sodium iodide, or potassium iodide. The present invention provides a method comprising:
[0044] The present invention also provides lipid particles containing amino lipid compounds, and uses of the lipid particles to deliver bioactive agents to cells. The present invention also includes the use of lipid particles containing amino lipid compounds as pharmaceuticals. Effect of the Invention
[0045] The amino lipid compound of the present invention has an alkynyl group, and the addition of alkyne lipid significantly increases membrane fusion to enhance mRNA release, resulting in a synergistic improvement in mRNA delivery.It can remain stable during circulation in vivo and be rapidly degraded in endosomes / lysosomes, significantly enhancing delivery efficiency.The preparation method of amino lipid compound has the advantages of easy availability of raw materials, mild reaction conditions, good reaction selectivity, high reaction yield, low requirements for equipment and devices, simple operation, etc. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0046] The present invention will now be described in more detail.
[0047] As used herein, the term "optionally substituted" means that one or more hydrogen atoms bonded to an atom or group are independently unsubstituted or substituted with one or more substituents, for example 1, 2, 3 or 4 substituents, which substituents are independently selected from deuterium (D), halogen, -OH, mercapto, cyano, -CD3, C1-C6 alkyl (preferably C1-C3 alkyl), C2-C6 alkenyl, C2-C6 alkynyl, cycloalkyl (preferably C3-C8 cycloalkyl), aryl, heterocyclyl (preferably 3-8 membered heterocyclyl), heteroaryl, arylC1-C6 alkyl-, heteroarylC1-C6 alkyl, C1-C6 haloalkyl, -OC1-C6 alkyl (preferably -OC1-C6 alkyl), -OC1-C6 alkyl, -OC ... C3 alkyl), -OC2-C6 alkenyl, OC1-C6 alkylphenyl, C1-C6 alkyl-OH (preferably C1-C4 alkyl-OH), C1-C6 alkyl-SH, C1-C6 alkyl-O-C1-C6 alkyl, OC1-C6 haloalkyl, NH2, C1-C6 alkyl-NH2 (preferably C1-C3 alkyl-NH2), -N(C1-C6 alkyl)2 (preferably -N(C1-C3 alkyl)2), -NH(C1-C6 alkyl) (preferably -NH(C1-C3 alkyl)), -N(C1-C6 alkyl)(C1-C6 alkylphenyl), -NH(C1-C6 alkylphenyl), nitro, -C(O)-OH, -C(O)OC1-C6 alkyl (preferably -C(O)OC1-C3 alkyl), -CONR i R ii (R in the formula i and R iiis H, D and C1-C6 alkyl, preferably C1-C3 alkyl), -NHC(O)(C1-C6 alkyl), -NHC(O)(phenyl), -N(C1-C6 alkyl)C(O)(C1-C6 alkyl), -N(C1-C6 alkyl)C(O)(phenyl), -C(O)C1-C6 alkyl, -C(O)heteroaryl (preferably -C(O)-5-7 membered heteroaryl), -C(O)C1-C6 alkylphenyl, -C(O)C1-C6 haloalkyl, -OC(O)C1-C6 alkyl and -NHS(O)2(C1-C6 alkyl), -S(O)2-C1-C6 haloalkyl, -S(O)2NH2, -S(O)2NH(C1-C6 alkyl), -S(O)2NH(phenyl), -NHS(O)2(C1-C6 alkyl), -NHS(O)2(phenyl) and -NHS(O)2(C1-C6 haloalkyl), wherein said alkyl, cycloalkyl, phenyl, aryl, -S(O)2-C1-C6 alkyl, -S(O)2-phenyl, -S(O)2-C1-C6 haloalkyl, -S(O)2NH2, -S(O)2NH(C1-C6 alkyl), -S(O)2NH(phenyl), -NHS(O)2(C1-C6 alkyl), -NHS(O)2(phenyl) and -NHS(O)2(C1-C6 haloalkyl), Each of the aryl, heterocyclyl and heteroaryl may optionally be selected from the following substituents: halogen, -OH, -NH2, cycloalkyl, 3-8 membered heterocyclyl, C1-C4 alkyl, C1-C4 haloalkyl-, -OC1-C4 alkyl, -C1-C4 alkyl-OH, -C1-C4 alkyl-O-C1-C4 alkyl, -OC1-C4 haloalkyl, cyano, nitro, -C(O)-OH, -C(O)OC1-C6 alkyl, -CON(C1-C6 alkyl)2, -CONH(C1-C6 alkyl). , -CONH2, -NHC(O)(C1-C6 alkyl), -NH(C1-C6 alkyl)C(O)(C1-C6 alkyl), -SO2(C1-C6 alkyl), -SO2(phenyl), -SO2(C1-C6 haloalkyl), -SO2NH2, -SON2NH(C1-C6 alkyl), -SON2NH(phenyl), -NHSO2(C1-C6 alkyl), -NHSO2(phenyl) and -NHSO2(C1-C6 haloalkyl).
[0048] When an atom or group is substituted with multiple substituents, the multiple substituents may be the same or different.
[0049] The term "hydrocarbyl" as used herein means the group remaining after an aliphatic hydrocarbon loses one hydrogen atom, and includes linear or branched, saturated or unsaturated hydrocarbon groups including alkyl, alkenyl, and alkynyl, and preferably the hydrocarbyl group is a C1-C 10 hydrocarbyl, C1 to C6 hydrocarbyl, or C1 to C3 hydrocarbyl.
[0050] The term "alkyl" as used herein means a C1-C 24 Alkyl, C1-C 20 Alkyl, C1-C 18 Alkyl, C1-C 12 Alkyl, C1-C6 alkyl, C3-C 24 Alkyl, C3-C 20 Alkyl, C3-C 18 Alkyl, C3-C 12 Alkyl, C3-C6 alkyl, C6-C 24 Alkyl, C6-C 20 Alkyl, C6-C 18 Alkyl or C6-C 12 Refers to alkyl.
[0051] The term "alkenyl" as used herein means any C2-C 24 Alkenyl, C2-C 20 Alkenyl, C2-C 18 Alkenyl, C2-C 12 Alkenyl, C2-C6 alkenyl, C3-C 20 Alkenyl, C3-C 18 Alkenyl, C3-C 12 Alkenyl, C3-C6 alkenyl, C6-C 24 Alkenyl, C6-C 20 Alkenyl, C6-C 18 Alkenyl or C6-C 12 Refers to alkenyl.
[0052] The term "alkynyl" as used herein means a C-C 24 Alkynyl, C2-C 20 Alkynyl, C2-C 18Alkynyl, C2-C 12 Alkynyl, C2-C6 alkynyl, C3-C 20 Alkynyl, C3-C 18 Alkynyl, C3-C 12 Alkynyl, C3-C6 alkynyl, C6-C 24 Alkynyl, C6-C 20 Alkynyl, C6-C 18 Alkynyl or C6-C 12 Refers to alkynyl.
[0053] The term "acyl" as used herein refers to a hydrocarbyl-carbonyl group, preferably an acyl group having a C4 to C 24 Acyl, C6~C 18 Acyl, C6~C 12 Acyl, C6~C 10 Acyl, C4~C6 acyl, C2~C 12 acyl, or C2 to C6 acyl.
[0054] The term "alkoxy" as used herein refers to an alkyloxy group, preferably an alkoxy group having a C1 to C 10 It is alkoxy, more preferably, the alkoxy is C1 to C6 alkoxy, and most preferably, the alkoxy is C1 to C3 alkoxy.
[0055] The term "heterocycle" as used in the present invention refers to a saturated or unsaturated cyclic group containing a heteroatom selected from N, O, S, etc., preferably the heterocycle is an optionally substituted 4-10 membered heterocycle containing 1-6 heteroatoms selected from N, O, and S, or an optionally substituted 4-6 membered saturated heterocycle containing 1, 2 or 3 heteroatoms selected from N, O, and S. The heterocycle may be optionally substituted with one or more substituents as defined above for "optionally substituted".
[0056] Another embodiment of the present invention relates to lipid particles containing the amino lipid compounds described above. All of the compounds of the present invention have both hydrophobicity due to their long non-polar residues and hydrophilicity due to their amino groups. This amphiphilic property can be used to form lipid particles, such as lipid bilayers, micelles, liposomes, etc.
[0057] Within the scope of the present invention, the term "lipid particles" refers to nano-sized bodies (lipid nanoparticles) made from amino lipid compounds in an aqueous solution. These particles are, inter alia, lipid bilayer vesicles (liposomes), multilamellar vesicles or micelles.
[0058] In a preferred embodiment of the invention, the lipid particles are liposomes containing the amino lipid compounds described above. Within the scope of the present invention, liposomes are microvesicles composed of a bilayer of lipid amphipathic (amphiphilic) molecules that encapsulate an aqueous compartment.
[0059] Liposome formation is not a spontaneous process. Lipid vesicles first form when lipids are placed in water, resulting in the formation of a bilayer or a series of bilayers, each separated by a water molecule. Liposomes can be made by sonicating lipid vesicles in water.
[0060] Within the scope of the present invention, the term "lipid bilayer" refers to a thin film made up of two layers of lipid molecules. The term "micelle" refers to an aggregate of surfactant molecules dispersed in a liquid colloid. Typical micelles in aqueous solutions form aggregates with hydrophilic head regions on contact with water and chelate hydrophobic single tail regions in the center of the micelle.
[0061] Within the scope of the present invention, the term "cell" is used in general terms and includes individual cells, tissues, organs, insect cells, avian cells, fish cells, amphibian cells, mammalian cells, primary cells, continuous cell lines, stem cells and / or genetically engineered cells, such as cultures of recombinant cells expressing heterologous polypeptides or proteins, e.g., cells expressing heterologous polypeptides or proteins, such as growth factors or blood factors.
[0062] In a preferred embodiment, the lipid particle or liposome further contains a helper lipid. In a preferred embodiment, the helper lipid is a non-cationic lipid. In a more preferred embodiment, the helper lipid is a non-cationic phospholipid. Within the scope of the present invention, the non-cationic lipid may contain a cationic functional group (e.g., an ammonium group), but must contain at least an anionic functional group to neutralize the molecule. The totality of all functional groups in the lipid molecule must be non-cationic. Liposomes consisting of a mixture of cationic amino lipids and non-cationic (neutral) phospholipids are most effective for nucleic acid delivery to cells. In an even more preferred embodiment, the non-cationic lipid is DOPE or DSPC.
[0063] In a further preferred embodiment, the lipid particle or liposome further comprises a sterol. Sterols, like cholesterol, are natural components in cell membranes. Sterols can be used to stabilize the particles and aid in their integration with the cell membrane.
[0064] In another embodiment of the present invention, the lipid particle or liposome further contains a bioactive agent. Within the scope of the present invention, a bioactive agent is one that has a biological effect when introduced into a cell or host, for example, by stimulating an immune or inflammatory response, by exerting an enzymatic activity, or by complementing a mutation, and bioactive agents include, among others, nucleic acids, peptides, proteins, antibodies, and small molecules. When liposomes are used to encapsulate drug substances either within the lipid bilayer or in the internal aqueous space of the liposome, the term "liposomal drug" can be adopted.
[0065] In a most preferred embodiment, the bioactive agent is a nucleic acid, hi another preferred embodiment, the bioactive agent is a member selected from the group consisting of antineoplastic agents, antibiotics, immunomodulatory agents, anti-inflammatory agents, agents acting on the central nervous system, polypeptides or polypeptoids.
[0066] In yet another embodiment, lipid particles or liposomes further contain at least one polyethylene glycol (PEG)-lipid. PEG lipids serve to protect particles and their cargo from degradation in vitro and in vivo. In addition, PEG forms a protective layer on the liposome surface, increasing circulation time in vivo. It may be used in liposomal drug delivery (PEG-liposome). Preferably, the polyethylene glycol lipid is PEG2000-DMG.
[0067] The lipid particles or liposomes containing a bioactive agent can be used to deliver any of a variety of therapeutic agents into cells. The present invention encompasses the use of lipid particles, particularly liposomes, as described above, to deliver a bioactive agent to a cell.
[0068] Preferably, the bioactive agent is a nucleic acid, including but not limited to messenger RNA (mRNA), antisense oligonucleotides, DNA, plasmids, ribosomal RNA (rRNA), microRNA (miRNA), transfer RNA (tRNA), small inhibitory RNA (siRNA) and small nuclear RNA (snRNA). The bioactive agent may be antineoplastic drugs, antibiotics, immunomodulators, anti-inflammatory drugs, drugs acting on the central nervous system, antigens or fragments thereof, proteins, peptides, polypeptoids, vaccines and small molecules or mixtures thereof. As indicated above, lipid particles or liposomes containing amino lipid compounds as defined in the present invention are suitable for delivering bioactive agents to cells. A wide variety of different amino lipid compounds that can be synthesized by the general synthesis methods mentioned can be screened for specific characteristics that are imparted to the liposomes, important characteristics being, for example, transfection efficiency, cytotoxicity, adhesion of the drug delivered inside the cell, stability of the liposomes, size of the liposomes, etc. The method allows the creation of liposomes that are specifically adapted for a specific application.
[0069] For example, lipid particles or liposomes may be used to transfect multicellular tissues or organisms, offering the possibility of novel therapeutic treatments of patients.
[0070] According to the present invention, the patient may be any mammal, preferably selected from the group consisting of humans, mice, rats, pigs, cats, dogs, horses, goats, cows, monkeys and / or others. Most preferably, the patient is a human.
[0071] An important embodiment of the present invention is the pharmaceutical use of said lipid particles or liposomes containing an amino lipid compound according to one of the formulae (I-III).
[0072] In particular, the lipid particles or liposomes can be administered to a patient for use in gene therapy, genetic vaccination, antisense therapy, or interfering RNA therapy. (1) The lipid particles of the present invention can deliver nucleic acids for gene therapy. To achieve the purpose of treatment, foreign genes are introduced into target cells via the amino lipids of the present invention to correct or reverse diseases caused by defective and abnormal genes. It also includes the application of technologies such as gene recombination, that is, through gene transfer technology, exogenous genes are inserted into appropriate recipient cells of patients, so that the products produced by the exogenous genes can treat certain diseases, such as common lung cancer, stomach cancer, liver cancer, esophageal cancer, colon cancer, pancreatic cancer, brain cancer, lymphatic cancer, blood cancer, prostate cancer, etc. Gene-edited nucleic acid materials may be introduced for the treatment of various genetic diseases, such as hemophilia, thalassemia, Gaucher's disease, etc. (2) The lipid particles of the present invention can be used for vaccination. The lipid particles or liposomes of the present invention can be used to deliver antigens or nucleic acids encoding antigens. The lipid particles of the present invention can be used to induce immune responses to a wide variety of antigens for the treatment and / or prevention of a number of conditions, including, but not limited to, cancer, allergies, toxicity and infection by pathogens, such as viruses, bacteria, fungi, and other pathogenic organisms.
[0073] The above-mentioned lipid particles can be used to prepare drugs for the transfer of nucleic acids, preferably the nucleic acids are RNA, messenger RNA (mRNA), antisense oligonucleotides, DNA, plasmids, ribosomal RNA (rRNA), microRNA (miRNA), transfer RNA (tRNA), small inhibitory RNA (siRNA), and small nuclear RNA (snRNA).
[0074] In order to make the objectives, technical solutions and advantages of the embodiments of the present invention clearer, the technical solutions in the embodiments of the present invention are clearly and completely described below with reference to specific examples. Obviously, the described examples are only a part, not all, of the embodiments of the present invention. Based on the embodiments of the present invention, all other embodiments obtained by those skilled in the art without creative efforts shall fall within the protection scope of the present invention. EXAMPLES
[0075] Synthesis of 1-octylnonyl 8-bromooctanoate
[0076] [ka]
[0077] In a 250 mL reaction flask, 8-bromooctanoic acid (22.3 g, 100 mmol), heptadecan-9-ol (25.6 g, 100 mmol), and dichloromethane (100 mL) were added successively. The mixture was stirred to dissolve. Then, 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (23.0 g, 120 mmol), 4-dimethylaminopyridine (0.61 g, 5 mmol), and N,N-diisopropylethylamine (25.8 g, 200 mmol) were further added. The resulting mixture was reacted at room temperature for 2 hours, washed with water three times, dried over anhydrous sodium sulfate, concentrated, and then purified by flash column chromatography system (hexane:ethyl acetate=10:1 to 3:1) to produce 1-octylnonyl 8-bromooctanoate (41.5 g, 90%). EXAMPLES
[0078] Synthesis of hept-2-ynyl 8-bromooctanoate
[0079] [ka]
[0080] In a 100 mL reaction flask, 8-bromooctanoic acid (2.23 g, 10 mmol), hept-2-yn-1-ol (1.12 g, 10 mmol), and dichloromethane (30 mL) were added successively. The mixture was stirred to dissolve. Then, 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (2.3 g, 12 mmol), 4-dimethylaminopyridine (0.06 g, 0.5 mmol), and N,N-diisopropylethylamine (2.58 g, 20 mmol) were further added. The resulting mixture was reacted at room temperature for 2 hours, washed with water three times, dried over anhydrous sodium sulfate, concentrated, and then purified by flash column chromatography system (hexane:ethyl acetate=10:1 to 2:1) to produce hept-2-ynyl 8-bromooctanoate (3.01 g, 95%). EXAMPLES
[0081] Synthesis of 1-Octylnonyl 8-(3-hydroxypropylamino)octanoate
[0082] [ka]
[0083] In a 100 mL reaction flask, 1-octylnonyl 8-bromooctanoate (4.61 g, 10 mmol), 3-amino-1-propanol (7.5 g, 100 mmol), and ethanol (30 mL) were added successively. The mixture was stirred to dissolve. Then, N,N-diisopropylethylamine (2.58 g, 20 mmol) was further added. The resulting mixture was reacted at room temperature for 24 hours, after which dichloromethane (100 mL) was added, washed with water three times, dried over anhydrous sodium sulfate, concentrated, and then purified by flash column chromatography system (dichloromethane:methanol=20:1 to 5:1) to produce 1-octylnonyl 8-(3-hydroxy-propylamino)octanoate (3.32 g, 73%). EXAMPLES
[0084] Synthesis of compound 1
[0085] [ka]
[0086] In a 100 mL reaction flask, 1-octylnonyl 8-(3-hydroxy-propylamino)octanoate (455 mg, 1 mmol), hept-2-ynyl 8-bromooctanoate (380 mg, 1.2 mmol), and acetonitrile (20 mL) were added successively. The mixture was stirred to dissolve. Then, potassium carbonate (276 mg, 2 mmol), and potassium iodide (166 mg, 1 mmol) were further added. The resulting mixture was reacted at room temperature for 24 hours, after which dichloromethane (100 mL) was added, washed with water three times, dried over anhydrous sodium sulfate, concentrated, and then purified by flash column chromatography system (dichloromethane:methanol=20:1 to 5:1) to produce compound 1 (560 mg, 81%). 1 H NMR (400 MHz, CDCl3) δ: ppm 4.88 (m, 1H); 4.65 (m, 2H); 3.68-3.46 (m, 2H); 2.77-2.37 (m, 8H); 2.28 (m, 4H); 1.75-1.42 (m, 14H); 1.39-1.18 (m, 40H); 0.89 (m, 9H). ESI-MS C 43 H 82 No.5 + [M+H] + Calculated value 692.6, measured value 692.7 EXAMPLES
[0087] Synthesis of decan-2-yn-1-yl 8-bromooctanoate
[0088] [ka]
[0089] In a 100 mL reaction flask, 8-bromooctanoic acid (2.23 g, 10 mmol), 2-decyn-1-ol (1.54 g, 10 mmol), and dichloromethane (30 mL) were added successively. The mixture was stirred to dissolve. Then, 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (2.3 g, 12 mmol), 4-dimethylaminopyridine (0.06 g, 0.5 mmol), and N,N-diisopropylethylamine (2.58 g, 20 mmol) were further added. The resulting mixture was reacted at room temperature for 2 hours, washed with water three times, dried over anhydrous sodium sulfate, concentrated, and then purified by flash column chromatography system (hexane:ethyl acetate=10:1 to 2:1) to produce decan-2-yn-1-yl 8-bromooctanoate (3.3 g, 92%). EXAMPLES
[0090] Synthesis of compound 4
[0091] [ka]
[0092] In a 100 mL reaction flask, 1-octylnonyl 8-(3-hydroxy-propylamino)octanoate (455 mg, 1 mmol), decan-2-yn-1-yl 8-bromooctanoate (380 mg, 1.2 mmol), and acetonitrile (20 mL) were added successively. The mixture was stirred to dissolve. Then, potassium carbonate (276 mg, 2 mmol), and potassium iodide (166 mg, 1 mmol) were further added. The resulting mixture was reacted at room temperature for 24 hours, after which dichloromethane (100 mL) was added, washed with water three times, dried over anhydrous sodium sulfate, concentrated, and then purified by flash column chromatography system (dichloromethane:methanol=20:1 to 5:1) to produce compound 4 (558 mg, 76%). 1H NMR (400 MHz, CDCl3) δ: ppm 4.87 (m, 1H); 4.68 (m, 2H); 3.64-3.42 (m, 2H); 2.79-2.38 (m, 8H); 2.27 (m, 4H); 1.76-1.43 (m, 14H); 1.41-1.16 (m, 46H); 0.88 (m, 9H). ESI-MS C 46 H 88 No.5 + [M+H] + Calculated value 734.7, measured value 734.7. EXAMPLES
[0093] Synthesis of decan-3-yn-1-yl 8-bromooctanoate
[0094] [ka]
[0095] In a 100 mL reaction flask, 8-bromooctanoic acid (2.23 g, 10 mmol), 3-decyn-1-ol (1.54 g, 10 mmol), and dichloromethane (30 mL) were added successively. The mixture was stirred to dissolve. Then, 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (2.3 g, 12 mmol), 4-dimethylaminopyridine (0.06 g, 0.5 mmol), and N,N-diisopropylethylamine (2.58 g, 20 mmol) were further added. The resulting mixture was reacted at room temperature for 2 hours, washed with water three times, dried over anhydrous sodium sulfate, concentrated, and then purified by flash column chromatography system (hexane:ethyl acetate=10:1 to 2:1) to produce decan-3-yn-1-yl 8-bromooctanoate (3.2 g, 89%). EXAMPLES
[0096] Synthesis of compound 7
[0097] [ka]
[0098] In a 100 mL reaction flask, 1-octylnonyl 8-(3-hydroxy-propylamino)octanoate (455 mg, 1 mmol), decan-3-yn-1-yl 8-bromooctanoate (380 mg, 1.2 mmol), and acetonitrile (20 mL) were added successively. The mixture was stirred to dissolve. Then, potassium carbonate (276 mg, 2 mmol), and potassium iodide (166 mg, 1 mmol) were further added. The resulting mixture was reacted at room temperature for 24 hours, after which dichloromethane (100 mL) was added, washed with water three times, dried over anhydrous sodium sulfate, concentrated, and then purified by flash column chromatography system (dichloromethane:methanol=20:1 to 5:1) to produce compound 7 (558 mg, 76%). 1 H NMR (400 MHz, CDCl3) δ: ppm 4.89 (m, 1H); 4.67 (m, 2H); 3.66-3.43 (m, 2H); 2.78-2.36 (m, 10H); 2.28 (m, 4H); 1.77-1.45 (m, 14H); 1.40-1.15 (m, 44H); 0.89 (m, 9H). ESI-MS C 46 H 88 No.5 + [M+H] + Calculated value 734.7, measured value 734.8. EXAMPLES
[0099] Synthesis of 1-octylnonyl 8-((2-hydroxyethyl)amino)octanoate
[0100] [ka]
[0101] In a 100 mL reaction flask, 1-octylnonyl 8-bromooctanoate (4.61 g, 10 mmol), 2-amino-1-ethanol (6.1 g, 100 mmol), and ethanol (30 mL) were added successively. The mixture was stirred to dissolve. Then, N,N-diisopropylethylamine (2.58 g, 20 mmol) was further added. The resulting mixture was reacted at room temperature for 24 hours, after which dichloromethane (100 mL) was added, washed with water three times, dried over anhydrous sodium sulfate, concentrated, and then purified by flash column chromatography system (dichloromethane:methanol=20:1 to 5:1) to produce 1-octylnonyl 8-((2-hydroxyethyl)amino)octanoate (3.35 g, 76%). EXAMPLES
[0102] Synthesis of compound 14
[0103] [ka]
[0104] In a 100 mL reaction flask, 1-octylnonyl 8-((2-hydroxyethyl)amino)octanoate (442 mg, 1 mmol), decan-3-yn-1-yl 8-bromooctanoate (380 mg, 1.2 mmol), and acetonitrile (20 mL) were added successively. The mixture was stirred to dissolve. Then, potassium carbonate (276 mg, 2 mmol), and potassium iodide (166 mg, 1 mmol) were further added. The resulting mixture was reacted at room temperature for 24 hours, after which dichloromethane (100 mL) was added, washed with water three times, dried over anhydrous sodium sulfate, concentrated, and then purified by flash column chromatography system (dichloromethane:methanol=20:1 to 5:1) to produce compound 14 (511 mg, 71%). 1H NMR (400 MHz, CDCl3) δ: ppm 4.89 (m, 1H); 4.67 (m, 2H); 3.66-3.43 (m, 2H); 2.78-2.36 (m, 10H); 2.28 (m, 4H); 1.77-1.45 (m, 14H); 1.40-1.15 (m, 42H); 0.89 (m, 9H). ESI-MS C 45 H 86 No.5 + [M+H] + Calculated value: 720.7, measured value: 720.8. EXAMPLES
[0105] Synthesis of 4-nonyn-1-yl 8-bromooctanoate
[0106] [ka]
[0107] In a 100 mL reaction flask, 8-bromooctanoic acid (2.23 g, 10 mmol), 4-nonyn-1-ol (1.4 g, 10 mmol), and dichloromethane (30 mL) were added successively. The mixture was stirred to dissolve. Then, 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (2.3 g, 12 mmol), 4-dimethylaminopyridine (0.06 g, 0.5 mmol), and N,N-diisopropylethylamine (2.58 g, 20 mmol) were further added. The resulting mixture was reacted at room temperature for 2 hours, washed with water three times, dried over anhydrous sodium sulfate, concentrated, and then purified by flash column chromatography system (hexane:ethyl acetate=10:1 to 2:1) to produce 4-nonyn-1-yl 8-bromooctanoate (3.0 g, 88%). EXAMPLES
[0108] Synthesis of 1-Octylnonyl 8-((4-hydroxybutyl)amino)octanoate
[0109] [ka]
[0110] In a 100 mL reaction flask, 1-octylnonyl 8-bromooctanoate (4.61 g, 10 mmol), 4-amino-1-butanol (8.9 g, 100 mmol), and ethanol (30 mL) were added successively. The mixture was stirred to dissolve. Then, N,N-diisopropylethylamine (2.58 g, 20 mmol) was further added. The resulting mixture was reacted at room temperature for 24 hours, after which dichloromethane (100 mL) was added, washed with water three times, dried over anhydrous sodium sulfate, concentrated, and then purified by flash column chromatography system (dichloromethane:methanol=20:1 to 5:1) to produce 1-octylnonyl 8-((4-hydroxylbutyl)amino)octanoate (3.71 g, 79%). EXAMPLES
[0111] Synthesis of compound 17
[0112] [ka]
[0113] In a 100 mL reaction flask, 1-octylnonyl 8-((4-hydroxylbutyl)amino)octanoate (442 mg, 1 mmol), 4-nonyn-1-yl 8-bromooctanoate (414 mg, 1.2 mmol), and acetonitrile (20 mL) were added successively. The mixture was stirred to dissolve. Then, potassium carbonate (276 mg, 2 mmol), and potassium iodide (166 mg, 1 mmol) were further added. The resulting mixture was reacted at room temperature for 24 hours, after which dichloromethane (100 mL) was added, washed with water three times, dried over anhydrous sodium sulfate, concentrated, and then purified by flash column chromatography system (dichloromethane:methanol=20:1 to 5:1) to produce compound 17 (550 mg, 75%). 1H NMR (400 MHz, CDCl3) δ: ppm 4.91 (m, 1H); 4.68 (m, 2H); 3.68-3.44 (m, 2H); 2.79-2.36 (m, 10H); 2.29 (m, 4H); 1.78-1.46 (m, 14H); 1.42-1.16 (m, 44H); 0.89 (m, 9H). ESI-MS C 46 H 88 No.5 + [M+H] + Calculated value 734.7, measured value 734.7. EXAMPLES
[0114] Synthesis of 1-octylnonyl 8-((3-hydroxycyclobutyl)amino)octanoate
[0115] [ka]
[0116] In a 100 mL reaction flask, 1-octylnonyl 8-bromooctanoate (4.61 g, 10 mmol), 3-aminocyclobutanol (8.7 g, 100 mmol), and ethanol (30 mL) were added successively. The mixture was stirred to dissolve. Then, N,N-diisopropylethylamine (2.58 g, 20 mmol) was further added. The resulting mixture was reacted at room temperature for 24 hours, after which dichloromethane (100 mL) was added, washed with water three times, dried over anhydrous sodium sulfate, concentrated, and then purified by flash column chromatography system (dichloromethane:methanol=20:1 to 5:1) to produce 1-octylnonyl 8-((3-hydroxycyclobutyl)amino)octanoate (3.23 g, 69%). EXAMPLES
[0117] Synthesis of compound 18
[0118] [ka]
[0119] In a 100 mL reaction flask, 1-octylnonyl 8-((3-hydroxycyclobutyl)amino)octanoate (468 mg, 1 mmol), 4-nonyn-1-yl 8-bromooctanoate (414 mg, 1.2 mmol), and acetonitrile (20 mL) were added successively. The mixture was stirred to dissolve. Then, potassium carbonate (276 mg, 2 mmol), and potassium iodide (166 mg, 1 mmol) were further added. The resulting mixture was reacted at room temperature for 24 hours, after which dichloromethane (100 mL) was added, washed with water three times, dried over anhydrous sodium sulfate, concentrated, and then purified by flash column chromatography system (dichloromethane:methanol=20:1 to 5:1) to produce compound 18 (600 mg, 82%). 1 H NMR (400 MHz, CDCl3) δ: ppm 4.90 (m, 1H); 4.68 (m, 2H); 3.68-3.44 (m, 1H); 2.79-2.36 (m, 10H); 2.29 (m, 3H); 1.78-1.46 (m, 14H); 1.42-1.16 (m, 44H); 0.89 (m, 9H). ESI-MS C 46 H 86 No.5 + [M+H] + Calculated value 732.7, measured value 732.7. EXAMPLES
[0120] Synthesis of 4-nonyn-1-yl 5-bromopentanoate
[0121] [ka]
[0122] In a 100 mL reaction flask, 5-bromopentanoic acid (1.81 g, 10 mmol), 4-nonyn-1-ol (1.4 g, 10 mmol), and dichloromethane (30 mL) were added successively. The mixture was stirred to dissolve. Then, 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (2.3 g, 12 mmol), 4-dimethylaminopyridine (0.06 g, 0.5 mmol), and N,N-diisopropylethylamine (2.58 g, 20 mmol) were further added. The resulting mixture was reacted at room temperature for 2 hours, washed with water three times, dried over anhydrous sodium sulfate, concentrated, and then purified by flash column chromatography system (hexane:ethyl acetate=10:1 to 2:1) to produce 4-nonyn-1-yl 5-bromopentanoate (2.7 g, 89%). EXAMPLES
[0123] Synthesis of compound 22
[0124] [ka]
[0125] In a 100 mL reaction flask, 1-octylnonyl 8-((4-hydroxylbutyl)amino)octanoate (442 mg, 1 mmol), 4-nonyn-1-yl 5-bromopentanoate (364 mg, 1.2 mmol), and acetonitrile (20 mL) were added successively. The mixture was stirred to dissolve. Then, potassium carbonate (276 mg, 2 mmol), potassium iodide (166 mg, 1 mmol) were further added. The resulting mixture was reacted at room temperature for 24 hours, after which dichloromethane (100 mL) was added, washed with water three times, dried over anhydrous sodium sulfate, concentrated, and then purified by flash column chromatography system (dichloromethane:methanol=20:1 to 5:1) to produce compound 22 (581 mg, 84%). 1H NMR (400 MHz, CDCl3) δ: ppm 4.91 (m, 1H); 4.68 (m, 2H); 3.68-3.44 (m, 2H); 2.79-2.36 (m, 10H); 2.29 (m, 4H); 1.78-1.46 (m, 14H); 1.42-1.16 (m, 38H); 0.89 (m, 9H). ESI-MS C 43 H 82 No.5 + [M+H] + Calculated value 692.6, measured value 692.7. EXAMPLES
[0126] Synthesis of 4-nonyn-1-yl 10-bromodecanoate
[0127] [ka]
[0128] In a 100 mL reaction flask, 10-bromodecanoic acid (2.51 g, 10 mmol), 4-nonyn-1-ol (1.4 g, 10 mmol), and dichloromethane (30 mL) were added successively. The mixture was stirred to dissolve. Then, 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (2.3 g, 12 mmol), 4-dimethylaminopyridine (0.06 g, 0.5 mmol), and N,N-diisopropylethylamine (2.58 g, 20 mmol) were further added. The resulting mixture was reacted at room temperature for 2 hours, washed with water three times, dried over anhydrous sodium sulfate, concentrated, and then purified by flash column chromatography system (hexane:ethyl acetate=10:1 to 2:1) to produce 4-nonyn-1-yl 10-bromodecanoate (2.95 g, 79%). EXAMPLES
[0129] Synthesis of compound 23
[0130] [ka]
[0131] In a 100 mL reaction flask, 1-octylnonyl 8-((2-hydroxylbutyl)amino)octanoate (442 mg, 1 mmol), 4-nonyn-1-yl 10-bromodecanoate (373 mg, 1.2 mmol), and acetonitrile (20 mL) were added successively. The mixture was stirred to dissolve. Then, potassium carbonate (276 mg, 2 mmol), and potassium iodide (166 mg, 1 mmol) were further added. The resulting mixture was reacted at room temperature for 24 hours, after which dichloromethane (100 mL) was added, washed with water three times, dried over anhydrous sodium sulfate, concentrated, and then purified by flash column chromatography system (dichloromethane:methanol=20:1 to 5:1) to produce compound 23 (648 mg, 85%). 1 H NMR (400 MHz, CDCl3) δ: ppm 4.90 (m, 1H); 4.67 (m, 2H); 3.69-3.43 (m, 2H); 2.76-2.34 (m, 10H); 2.28 (m, 4H); 1.79-1.47 (m, 14H); 1.44-1.18 (m, 48H); 0.88 (m, 9H). ESI-MS C 48 H 92 No.5 + [M+H] + Calculated value 762.7, measured value 762.7. EXAMPLES
[0132] Synthesis of 4-nonyn-1-yl 14-bromotetradecanoate
[0133] [ka]
[0134] In a 100 mL reaction flask, 14-bromotetradecanoic acid (3.07 g, 10 mmol), 4-nonyn-1-ol (1.4 g, 10 mmol), and dichloromethane (30 mL) were added successively. The mixture was stirred to dissolve. Then, 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (2.3 g, 12 mmol), 4-dimethylaminopyridine (0.06 g, 0.5 mmol), and N,N-diisopropylethylamine (2.58 g, 20 mmol) were further added. The resulting mixture was reacted at room temperature for 2 hours, washed with water three times, dried over anhydrous sodium sulfate, concentrated, and then purified by flash column chromatography system (hexane:ethyl acetate=10:1 to 2:1) to produce 4-nonyn-1-yl 14-bromotetradecanoate (3.51 g, 82%). EXAMPLES
[0135] Synthesis of compound 24
[0136] [ka]
[0137] In a 100 mL reaction flask, 1-octylnonyl 8-((4-hydroxylbutyl)amino)octanoate (442 mg, 1 mmol), 4-nonyn-1-yl 14-bromotetradecanoate (429 mg, 1.2 mmol), and acetonitrile (20 mL) were added successively. The mixture was stirred to dissolve. Then, potassium carbonate (276 mg, 2 mmol), and potassium iodide (166 mg, 1 mmol) were further added. The resulting mixture was reacted at room temperature for 24 hours, after which dichloromethane (100 mL) was added, washed with water three times, dried over anhydrous sodium sulfate, concentrated, and then purified by flash column chromatography system (dichloromethane:methanol=20:1 to 5:1) to produce compound 24 (654 mg, 80%). 1H NMR (400 MHz, CDCl3) δ: ppm 4.90 (m, 1H); 4.67 (m, 2H); 3.69-3.43 (m, 2H); 2.76-2.34 (m, 10H); 2.28 (m, 4H); 1.79-1.47 (m, 14H); 1.44-1.18 (m, 56H); 0.88 (m, 9H). ESI-MS C 52 H 100 No.5 + [M+H] + Calculated value: 818.7, measured value: 818.8. EXAMPLES
[0138] Synthesis of nona-5-yl 8-bromooctanoate
[0139] [ka]
[0140] In a 250 mL reaction flask, 8-bromooctanoic acid (22.3 g, 100 mmol), 5-nonanol (14.4 g, 100 mmol), and dichloromethane (100 mL) were added successively. The mixture was stirred to dissolve. Then, 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (23.0 g, 120 mmol), 4-dimethylaminopyridine (0.61 g, 5 mmol), and N,N-diisopropylethylamine (25.8 g, 200 mmol) were further added. The resulting mixture was reacted at room temperature for 2 hours, washed with water three times, dried over anhydrous sodium sulfate, concentrated, and then purified by flash column chromatography system (hexane:ethyl acetate=10:1 to 3:1) to produce non-5-yl 8-bromooctanoate (27.9 g, 82%). EXAMPLES
[0141] Synthesis of non-5-yl 8-((3-hydroxypropyl)amino)octanoate
[0142] [ka]
[0143] In a 100 mL reaction flask, non-5-yl 8-bromooctanoate (3.49 g, 10 mmol), 3-amino-1-propanol (7.5 g, 100 mmol), and ethanol (30 mL) were added successively. The mixture was stirred to dissolve. Then, N,N-diisopropylethylamine (2.58 g, 20 mmol) was further added. The resulting mixture was reacted at room temperature for 24 hours, after which dichloromethane (100 mL) was added, washed with water three times, dried over anhydrous sodium sulfate, concentrated, and then purified by flash column chromatography system (dichloromethane:methanol=20:1 to 5:1) to produce non-5-yl 8-((3-hydroxypropyl)amino)octanoate (2.57 g, 75%). EXAMPLES
[0144] Synthesis of compound 25
[0145] [ka]
[0146] In a 100 mL reaction flask, non-5-yl 8-((3-hydroxypropyl)amino)octanoate (343 mg, 1 mmol), 4-nonyn-1-yl 14-bromotetradecanoate (429 mg, 1.2 mmol), and acetonitrile (20 mL) were added successively. The mixture was stirred to dissolve. Then, potassium carbonate (276 mg, 2 mmol), and potassium iodide (166 mg, 1 mmol) were further added. The resulting mixture was reacted at room temperature for 24 hours, after which dichloromethane (100 mL) was added, washed with water three times, dried over anhydrous sodium sulfate, concentrated, and then purified by flash column chromatography system (dichloromethane:methanol=20:1 to 5:1) to produce compound 25 (574 mg, 83%). 1H NMR (400 MHz, CDCl3) δ: ppm 4.90 (m, 1H); 4.67 (m, 2H); 3.69-3.43 (m, 2H); 2.76-2.34 (m, 10H); 2.28 (m, 4H); 1.79-1.47 (m, 14H); 1.44-1.18 (m, 38H); 0.88 (m, 9H). ESI-MS C 43 H 82 No.5 + [M+H] + Calculated value 692.6, measured value 692.7. EXAMPLES
[0147] Synthesis of undecane-5-yl 8-bromooctanoate
[0148] [ka]
[0149] In a 250 mL reaction flask, 8-bromooctanoic acid (22.3 g, 100 mmol), undecan-5-ol (17.2 g, 100 mmol), and dichloromethane (100 mL) were added successively. The mixture was stirred to dissolve. Then, 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (23.0 g, 120 mmol), 4-dimethylaminopyridine (0.61 g, 5 mmol), and N,N-diisopropylethylamine (25.8 g, 200 mmol) were further added. The resulting mixture was reacted at room temperature for 2 hours, washed with water three times, dried over anhydrous sodium sulfate, concentrated, and then purified by flash column chromatography system (hexane:ethyl acetate=10:1 to 3:1) to produce undecan-5-yl 8-bromooctanoate (29.7 g, 79%). EXAMPLES
[0150] Synthesis of 1-butylheptyl 8-(3-hydroxypropylamino)-octanoate
[0151] [ka]
[0152] In a 100 mL reaction flask, 1-butylheptyl 8-bromooctanoate (3.49 g, 10 mmol), 3-amino-1-propanol (7.5 g, 100 mmol), and ethanol (30 mL) were added successively. The mixture was stirred to dissolve. Then, N,N-diisopropylethylamine (2.58 g, 20 mmol) was further added. The resulting mixture was reacted at room temperature for 24 hours, after which dichloromethane (100 mL) was added, washed with water three times, dried over anhydrous sodium sulfate, concentrated, and then purified by flash column chromatography system (dichloromethane:methanol=20:1 to 5:1) to produce 1-butylheptyl 8-(3-hydroxy-propylamino)-octanoate (2.93 g, 79%). EXAMPLES
[0153] Synthesis of compound 26
[0154] [ka]
[0155] In a 100 mL reaction flask, 1-butylheptyl 8-(3-hydroxy-propylamino)-octanoate (371 mg, 1 mmol), 4-nonyn-1-yl 14-bromotetradecanoate (429 mg, 1.2 mmol), and acetonitrile (20 mL) were added successively. The mixture was stirred to dissolve. Then, potassium carbonate (276 mg, 2 mmol), and potassium iodide (166 mg, 1 mmol) were further added. The resulting mixture was reacted at room temperature for 24 hours, after which dichloromethane (100 mL) was added, washed with water three times, dried over anhydrous sodium sulfate, concentrated, and then purified by flash column chromatography system (dichloromethane:methanol=20:1 to 5:1) to produce compound 26 (583 mg, 81%). 1H NMR (400 MHz, CDCl3) δ: ppm 4.90 (m, 1H); 4.67 (m, 2H); 3.69-3.43 (m, 2H); 2.76-2.34 (m, 10H); 2.28 (m, 4H); 1.79-1.47 (m, 14H); 1.44-1.18 (m, 42H); 0.88 (m, 9H). ESI-MS C 45 H 86 No.5 + [M+H] + Calculated value: 720.7, measured value: 720.8. EXAMPLES
[0156] Synthesis of 1-octylundecyl 8-bromooctanoate
[0157] [ka]
[0158] In a 250 mL reaction flask, 8-bromooctanoic acid (22.3 g, 100 mmol), 9-nonadecanol (28.4 g, 100 mmol), and dichloromethane (100 mL) were added successively. The mixture was stirred to dissolve. Then, 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (23.0 g, 120 mmol), 4-dimethylaminopyridine (0.61 g, 5 mmol), and N,N-diisopropylethylamine (25.8 g, 200 mmol) were further added. The resulting mixture was reacted at room temperature for 2 hours, washed with water three times, dried over anhydrous sodium sulfate, concentrated, and then purified by flash column chromatography system (hexane:ethyl acetate=10:1 to 3:1) to produce 1-octylundecyl 8-bromooctanoate (38.1 g, 79%). EXAMPLES
[0159] Synthesis of 1-octylundecyl 8-((3-hydroxypropyl)amino)octanoate
[0160] [ka]
[0161] In a 100 mL reaction flask, 1-octylundecyl 8-bromooctanoate (4.89 g, 10 mmol), 3-amino-1-propanol (7.5 g, 100 mmol), and ethanol (30 mL) were added successively. The mixture was stirred to dissolve. Then, N,N-diisopropylethylamine (2.58 g, 20 mmol) was further added. The resulting mixture was reacted at room temperature for 24 hours, after which dichloromethane (100 mL) was added, washed with water three times, dried over anhydrous sodium sulfate, concentrated, and then purified by flash column chromatography system (dichloromethane:methanol=20:1 to 5:1) to produce 1-octylundecyl 8-((3-hydroxypropyl)amino)octanoate (3.97 g, 72%). EXAMPLES
[0162] Synthesis of compound 27
[0163] [ka]
[0164] In a 100 mL reaction flask, 1-octylundecyl 8-((3-hydroxypropyl)amino)octanoate (371 mg, 1 mmol), 4-nonyn-1-yl 5-bromopentanoate (364 mg, 1.2 mmol), and acetonitrile (20 mL) were added successively. The mixture was stirred to dissolve. Then, potassium carbonate (276 mg, 2 mmol), and potassium iodide (166 mg, 1 mmol) were further added. The resulting mixture was reacted at room temperature for 24 hours, after which dichloromethane (100 mL) was added, washed with water three times, dried over anhydrous sodium sulfate, concentrated, and then purified by flash column chromatography system (dichloromethane:methanol=20:1 to 5:1) to produce compound 27 (536 mg, 76%). 1H NMR (400 MHz, CDCl3) δ: ppm 4.90 (m, 1H); 4.67 (m, 2H); 3.69-3.43 (m, 2H); 2.76-2.34 (m, 10H); 2.28 (m, 4H); 1.79-1.47 (m, 14H); 1.44-1.18 (m, 40H); 0.88 (m, 9H). ESI-MS C 44 H 84 No.5 + [M+H] + Calculated value 706.6, measured value 706.6. EXAMPLES
[0165] Synthesis of 2-hexyldecyl 8-bromooctanoate
[0166] [ka]
[0167] In a 250 mL reaction flask, 8-bromooctanoic acid (22.3 g, 100 mmol), 2-hexyldecan-1-ol (24.2 g, 100 mmol), and dichloromethane (100 mL) were added successively. The mixture was stirred to dissolve. Then, 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (23.0 g, 120 mmol), 4-dimethylaminopyridine (0.61 g, 5 mmol), and N,N-diisopropylethylamine (25.8 g, 200 mmol) were further added. The resulting mixture was reacted at room temperature for 2 hours, washed with water three times, dried over anhydrous sodium sulfate, concentrated, and then purified by flash column chromatography system (hexane:ethyl acetate=10:1 to 3:1) to produce 2-hexyldecyl 8-bromooctanoate (38.1 g, 79%). EXAMPLES
[0168] Synthesis of 2-hexyldecyl 8-((3-hydroxypropyl)amino)octanoate
[0169] [ka]
[0170] In a 100 mL reaction flask, 2-hexyldecyl 8-bromooctanoate (4.89 g, 10 mmol), 3-amino-1-propanol (7.5 g, 100 mmol), and ethanol (30 mL) were added successively. The mixture was stirred to dissolve. Then, N,N-diisopropylethylamine (2.58 g, 20 mmol) was further added. The resulting mixture was reacted at room temperature for 24 hours, after which dichloromethane (100 mL) was added, washed with water three times, dried over anhydrous sodium sulfate, concentrated, and then purified by flash column chromatography system (dichloromethane:methanol=20:1 to 5:1) to produce 2-hexyldecyl 8-((3-hydroxypropyl)amino)octanoate (3.35 g, 76%). EXAMPLES
[0171] Synthesis of compound 28
[0172] [ka]
[0173] In a 100 mL reaction flask, 2-hexyldecyl 8-((3-hydroxypropyl)amino)octanoate (441 mg, 1 mmol), 4-nonyn-1-yl 5-bromopentanoate (364 mg, 1.2 mmol), and acetonitrile (20 mL) were added successively. The mixture was stirred to dissolve. Then, potassium carbonate (276 mg, 2 mmol), and potassium iodide (166 mg, 1 mmol) were further added. The resulting mixture was reacted at room temperature for 24 hours, after which dichloromethane (100 mL) was added, washed with water three times, dried over anhydrous sodium sulfate, concentrated, and then purified by flash column chromatography system (dichloromethane:methanol=20:1 to 5:1) to produce compound 28 (471 mg, 71%). 1H NMR (400 MHz, CDCl3) δ: ppm 4.90 (m, 1H); 4.67 (m, 2H); 3.69-3.43 (m, 2H); 2.76-2.34 (m, 10H); 2.28 (m, 4H); 1.79-1.47 (m, 14H); 1.44-1.18 (m, 34H); 0.88 (m, 9H). ESI-MS C 41 H 78 No.5 + [M+H] + Calculated value 664.6, measured value 664.6. EXAMPLES
[0174] Synthesis of 7-hydroxyheptyl 2-hexyldecanoate
[0175] [ka]
[0176] In a 250 mL reaction flask, 2-n-hexyldecanoic acid (25.6 g, 100 mmol), 1,7-heptanediol (66.0 g, 0.5 mol), and dichloromethane (150 mL) were added successively. The mixture was stirred to dissolve. Then, dicyclohexylcarbodiimide (20.6 g, 100 mmol) and 4-dimethylaminopyridine (0.61 g, 5 mmol) were further added. The resulting mixture was reacted at room temperature for 2 hours, washed with water three times, dried over anhydrous sodium sulfate, concentrated, and then purified by flash column chromatography system (hexane:ethyl acetate=5:1 to 1:1) to produce 7-hydroxyheptyl 2-hexyldecanoate (22.6 g, 61%). EXAMPLES
[0177] Synthesis of heptyl 7-((3-hydroxypropyl)amino) 2-hexyldecanoate
[0178] [ka]
[0179] In a 250 mL reaction flask, 7-hydroxyheptyl 2-hexyldecanoate (3.7 g, 10 mmol), dichloromethane (100 mL), and Dess-Martin periodinane (5.09 g, 12 mmol) were added in succession. The mixture was reacted with stirring at room temperature for 12 hours, washed three times with saturated sodium bicarbonate solution, washed once with water, and dried over anhydrous sodium sulfate. The drying agent was removed by filtration and washed with dichloromethane (10 mL). The organic phases were combined, followed by the addition of sodium triacetoxyborohydride (3.18 g, 15 mmol), followed by the addition of 3-amino-1-propanol (7.5 g, 100 mmol). The resulting mixture was reacted at room temperature for 24 hours, washed with water three times, dried over anhydrous sodium sulfate, concentrated, and then purified by flash column chromatography system (dichloromethane:methanol=20:1 to 5:1) to produce heptyl 7-((3-hydroxylpropyl)amino) 2-hexyldecanoate (3.03 g, 71%). EXAMPLES
[0180] Synthesis of 7-bromoheptylundec-2-ynoate
[0181] [ka]
[0182] In a 250 mL reaction flask, 8-bromoheptanol (19.5 g, 100 mmol), 2-undecynoic acid (18.2 g, 100 mmol), and dichloromethane (100 mL) were added successively. The mixture was stirred to dissolve. Then, 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (23.0 g, 120 mmol), 4-dimethylaminopyridine (0.61 g, 5 mmol), and N,N-diisopropylethylamine (25.8 g, 200 mmol) were further added. The resulting mixture was reacted at room temperature for 2 hours, washed with water three times, dried over anhydrous sodium sulfate, concentrated, and then purified by flash column chromatography system (hexane:ethyl acetate=10:1 to 3:1) to produce 7-bromoheptylundec-2-ynoate (25.4 g, 71%). EXAMPLES
[0183] Synthesis of compound 29
[0184] [ka]
[0185] In a 100 mL reaction flask, heptyl 7-((3-hydroxypropyl)amino) 2-hexyldecanoate (427 mg, 1 mmol), 7-bromoheptylundec-2-ynoate (431 mg, 1.2 mmol), and acetonitrile (20 mL) were added successively. The mixture was stirred to dissolve. Then, potassium carbonate (276 mg, 2 mmol), and potassium iodide (166 mg, 1 mmol) were further added. The resulting mixture was reacted at room temperature for 24 hours, after which dichloromethane (100 mL) was added, washed with water three times, dried over anhydrous sodium sulfate, concentrated, and then purified by flash column chromatography system (dichloromethane:methanol=20:1 to 5:1) to produce compound 29 (454 mg, 63%). 1H NMR (400 MHz, CDCl3) δ: ppm 4.88 (m, 4H); 3.67–3.43 (m, 2H); 2.76–2.14 (m, 9H); 1.79–1.47 (m, 12H); 1.44–1.18 (m, 48H); 9H). ESI-MS C 45 H 86 No.5 + [M+H] + Calculated value: 720.7, measured value: 720.8. EXAMPLES
[0186] Synthesis of 1-Octylnonyl 8-((3-(dimethylamino)propyl)amino)octanoate
[0187] [ka]
[0188] In a 100 mL reaction flask, 1-octylnonyl 8-bromooctanoate (4.61 g, 10 mmol), N,N-dimethylpropylenediamine (8.9 g, 100 mmol), and ethanol (30 mL) were added successively. The mixture was stirred to dissolve. Then, N,N-diisopropylethylamine (2.58 g, 20 mmol) was further added. The resulting mixture was reacted at room temperature for 24 hours, after which dichloromethane (100 mL) was added, washed with water three times, dried over anhydrous sodium sulfate, concentrated, and then purified by flash column chromatography system (dichloromethane:methanol=20:1 to 5:1) to produce 1-octylnonyl 8-((3-(dimethylamino)propyl)amino)octanoate (3.62 g, 75%). EXAMPLES
[0189] Synthesis of compound 31
[0190] [ka]
[0191] In a 100 mL reaction flask, 1-octylnonyl 8-((3-(dimethylamino)propyl)amino)octanoate (482 mg, 1 mmol), 4-nonyn-1-yl 8-bromooctanoate (414 mg, 1.2 mmol), and acetonitrile (20 mL) were added successively. The mixture was stirred to dissolve. Then, potassium carbonate (276 mg, 2 mmol), and potassium iodide (166 mg, 1 mmol) were further added. The resulting mixture was reacted at room temperature for 24 hours, after which dichloromethane (100 mL) was added, washed with water three times, dried over anhydrous sodium sulfate, concentrated, and then purified by flash column chromatography system (dichloromethane:methanol=20:1 to 5:1) to produce compound 31 (537 mg, 72%). 1 H NMR (400 MHz, CDCl3) δ: ppm 4.91 (m, 1H); 4.68 (m, 2H); 2.79-2.36 (m, 20H); 2.29 (m, 4H); 1.78-1.46 (m, 14H); 1.42-1.16 (m, 42H); 0.89 (m, 9H). ESI-MS C 47 H 91 N2O4 + [M+H] + Calculated value 747.7, measured value 747.8. EXAMPLES
[0192] Evaluation of the in vivo luciferase mRNA delivery capability of lipid nanoparticles prepared from amino lipid compounds Preparation of lipid nanoparticles: Preparation method I: The amino lipid compound described in the present invention was mixed and dissolved in absolute ethanol with a molar ratio of 45:10:42.5:2.5. Two microinjection pumps were used to control the ratio of the ethanol solution to the sodium acetate solution (50 mM, pH=4.0) to be 1:3. A crude solution of lipid nanoparticles was prepared in a microfluidic chip, and then dialyzed with 1XPBS at a controlled temperature of 4°C using a dialysis cassette (Fisher, MWCO 20,000) for 6 hours and filtered through a 0.22 μm microporous filter membrane before use. The mass ratio of the amino lipid compound to luciferase mRNA (Fluc mRNA) was about 10:1. The routes of administration included subcutaneous and intramuscular injection.
[0193] Preparation method II: The molar ratio of the amino lipid compound to DSPC, cholesterol, and PEG2000-DMG was 50:10:38.5:1.5, and the preparation method was the same as Preparation method I. The administration route was via the tail vein.
[0194] Animal preparation: 6-week-old male BALB / c mice weighing approximately 20 g were selected and fed in an SPF-grade feeding room. Animal experiments were performed in strict accordance with the guidelines of the national health authorities and the requirements of animal ethics.
[0195] In vivo delivery: Nine mice per group were randomly selected and lipid nanoparticles were injected at a dose of 0.5 mg / kg by three administration routes: subcutaneous, intramuscular, and tail vein, respectively (three animals per administration route). Six hours later, 200 μL of 10 mg / mL potassium D-fluorescein was injected into each mouse via the tail vein, and 10 minutes later, the mice were placed under an in vivo imaging system (IVIS-200, Xenogen) to observe the total fluorescence intensity of each mouse and record it by photography. The expression intensity of Fluc mRNA delivered by three administration routes of representative amino lipid compounds is shown in Tables 1-3 (Tables 2-4). DLin-MC3 was used as a control. In the in vivo delivery study of amino lipid compounds without introduction of alkynyl groups (36, 37) and their corresponding amino lipid compounds with introduction of alkynyl groups (17, 31), the delivery ability after introduction of alkynyl groups was significantly enhanced.
[0196] [Table 2A]
[0197] [Table 2B]
[0198] [Table 2C]
[0199] [Table 3A]
[0200] [Table 3B]
[0201] [Table 3C]
[0202] [Table 4A]
[0203] [Table 4B]
[0204] List of Abbreviations DNA: deoxyribonucleic acid. RNA: Ribonucleic acid DOPE: dioleoylphosphatidylethanolamine DSPC: Distearoylphosphatidylcholine PEG2000-DMG: 1-(monomethoxypolyethylene glycol)-2,3 dimyristoyl glycerol. KD: kilodaltons PBS: Phosphate buffer solution DLin-MC3: (6Z,9Z,28Z,31Z)-heptatriacont-6,9,28,31-tetraen-19-yl 4-(N,N-dimethylamino)butanoate.
Claims
1. The following structures (Va) and (Vb): [Case 1] (In the formula, x, y, m, and n are the same or different and each independently represents an integer from 1 to 12; L 1 is C 1 -C 24 alkylene; R 1 is selected from H, OR 1a , CN, -C(═O)OR 1a , -OC(═O)R 1a , -NR 1b C(═O)R 1a or -NR 1a R 1b , where R 1a and R 1b are each H or C 1 -C 12 hydrocarbyl; R 2 is a branched C 6 -C 24 alkyl or a branched C 6 -C 24 alkenyl; R 3 is H) or a pharma- ceutically acceptable salt or stereoisomer thereof.
2. R 2 But the following structure: [Case 2] 2. The compound of claim 1, or a pharma- ceutically acceptable salt or stereoisomer thereof, selected from one of:
3. A compound selected from the following compounds: [Table 1A] [Table 1B] [Table 1C] [Table 1D] [Table 1E] or a pharma- ceutically acceptable salt or stereoisomer thereof.
4. A lipid nanoparticle comprising a compound according to any one of claims 1 to 3.
5. Further comprising one or more of a helper lipid, a sterol, a polyethylene glycol lipid, and a bioactive agent; The lipid nanoparticle of claim 4.
6. The helper lipid is a non-cationic lipid. The lipid nanoparticle of claim 5.
7. The helper lipid is a non-cationic phospholipid. The lipid nanoparticle of claim 5.
8. The non-cationic lipid is DOPE or DSPC. The lipid nanoparticle of claim 6.
9. The sterol is cholesterol. The lipid nanoparticle of claim 5.
10. The polyethylene glycol lipid of claim 1, wherein the polyethylene glycol lipid is PEG2000-DMG. The lipid nanoparticle of claim 5.
11. The method of claim 10, wherein the bioactive agent is a nucleic acid, an anti-neoplastic agent, an antibiotic, an immunomodulator, an anti-inflammatory agent, an agent acting on the central nervous system, an antigen or a fragment thereof, a peptide, a protein, an antibody, a vaccine, or a small molecule. The lipid nanoparticle of claim 5.
12. The nucleic acid is RNA, messenger RNA (mRNA), an antisense oligonucleotide, DNA, a plasmid, ribosomal RNA (rRNA), microRNA (miRNA), transfer RNA (tRNA), small inhibitory RNA (siRNA) and small nuclear RNA (snRNA). The lipid nanoparticle of claim 11.
13. Use of a compound according to any one of claims 1 to 3 and a lipid nanoparticle according to any one of claims 4 to 12 in the manufacture of a medicament, said medicament being for use in gene therapy, gene vaccination, antisense therapy or therapy with interfering RNA. use.
14. The gene therapy is useful for the treatment of cancer and genetic diseases.
14. The use according to claim 13.
15. The cancer is one or more of lung cancer, stomach cancer, liver cancer, esophageal cancer, colon cancer, pancreatic cancer, brain cancer, lymphatic cancer, leukemia, and prostate cancer, and the genetic disease is one or more of hemophilia, thalassemia, and Gaucher disease.
15. The use according to claim 14.
16. The genetic vaccination is used to treat cancer, allergies, toxicity and infection by pathogens.
14. The use according to claim 13.
17. The method of claim 1, wherein the pathogen is selected from one or more of a virus, a bacterium, and a fungus.
17. The use according to claim 16.
18. Use of a compound according to any one of claims 1 to 3 and a lipid nanoparticle according to any one of claims 4 to 12 in the manufacture of a medicament for nucleic acid transfer.
19. The nucleic acid is RNA, messenger RNA (mRNA), an antisense oligonucleotide, DNA, a plasmid, ribosomal RNA (rRNA), microRNA (miRNA), transfer RNA (tRNA), small inhibitory RNA (siRNA) and small nuclear RNA (snRNA).
19. The use according to claim 18.
Citation Information
Patent Citations
Novel Lipid and Lipid Nanoparticle Formulations for Delivery of Nucleic Acids
JP2017522376A
Lipid nanoparticle mRNA vaccine
JP2020504764A
Compounds and compositions for intracellular delivery of therapeutic agents
JP2020514366A
Nucleoside-modified RNA for inducing an adaptive immune response
WO2016176330A1
